Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
Changhua site meets international regulatory standards for global medical applications
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
The unique soap-fusion of Gondhoraj lime and neem provides a refreshing skin-friendly experience
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 m
The MDR certification reafirms that these products meet the highest safety, quality, and regulatory standards
Subscribe To Our Newsletter & Stay Updated
